Financing drug discovery for orphan diseases.

Area of Science:

• Biomedical Finance
• Drug Development
• Orphan Diseases

Background:

• Translational medicine and drug development often require substantial capital investment, typically billions of dollars, through 'megafund' financing models.
• These large-scale investments aim to mitigate risks inherent in the drug discovery and development pipeline, facilitating long-term financial commitments.

Purpose of the Study:

• To evaluate the applicability of 'megafund' financing strategies to the field of orphan drug development.
• To determine the capital requirements for de-risking orphan drug portfolios using megafund models.
• To assess the potential financial returns of such investment vehicles in rare disease therapeutics.

Main Methods:

• Adaptation of existing megafund financing models for the unique characteristics of orphan drug development.
• Numerical simulations to model portfolio performance and risk assessment.
• Analysis of key factors influencing development costs, approval times, and failure rates in orphan therapeutics.

Main Results:

• Orphan drug development requires substantially less capital compared to broad translational medicine due to lower costs, faster regulatory pathways, and reduced failure correlations.
• A megafund of approximately US$575 million is projected to be sufficient for de-risking an orphan drug portfolio.
• Simulations indicate that such a fund, with 10-20 projects, can achieve double-digit expected rates of return.

Conclusions:

• Megafund financing is a viable and potentially highly effective strategy for orphan drug development.
• The unique attributes of rare diseases and their therapeutics significantly lower the capital needed to achieve financial viability.
• This approach could accelerate the development of treatments for rare diseases by attracting necessary investment with reduced financial barriers.